Achievement of treatment expectations ( 86.7 % ; Day 60 ) , satisfaction ( 81.7 % ; Day 60 ) , and satisfaction with the duration of treatment ( 61.6 % ; Day 90 ) were significantly better with onabotulinumtoxinA than placebo ( p < .001 ) for GL and CFL combined .